Interferon and interferon-induced cytokines as markers of impending clinical progression in ANA

Humans Cytokines Autoimmune Diseases Antibodies, Antinuclear Rheumatic Diseases Interferon-alpha Disease Progression
Cytokines Interferon Pre-clinical Systemic autoimmune rheumatic diseases

Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
10 02 2023
Historique:
received: 02 02 2022
accepted: 26 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

Elevated levels of interferons (IFNs) are a characteristic feature of systemic autoimmune rheumatic diseases (SARDs) and may be useful in predicting impending symptomatic progression in anti-nuclear antibody-positive (ANA A total of 280 subjects were studied, including 50 ANA Measurement of IFN-α levels by high-sensitivity ELISA or Simoa correlated much better with IFN-induced gene expression than measurement of CXCL-10 or Galectin-9 levels. Despite this, high CXCL-10 and Galectin-9 levels were better predictors of subsequent progression in ANA Easily performed ELISA assays for CXCL-10 and IFN-α can be used to predict ANA

Sections du résumé

BACKGROUND
Elevated levels of interferons (IFNs) are a characteristic feature of systemic autoimmune rheumatic diseases (SARDs) and may be useful in predicting impending symptomatic progression in anti-nuclear antibody-positive (ANA
METHODS
A total of 280 subjects were studied, including 50 ANA
RESULTS
Measurement of IFN-α levels by high-sensitivity ELISA or Simoa correlated much better with IFN-induced gene expression than measurement of CXCL-10 or Galectin-9 levels. Despite this, high CXCL-10 and Galectin-9 levels were better predictors of subsequent progression in ANA
CONCLUSION
Easily performed ELISA assays for CXCL-10 and IFN-α can be used to predict ANA

Identifiants

DOI: 10.1186/s13075-023-02997-w PMID: 36765391 PMC: PMC9912609
pubmed: 36765391
doi: 10.1186/s13075-023-02997-w
pii: 10.1186/s13075-023-02997-w
pmc: PMC9912609
doi:

Substances chimiques

Cytokines 0
Antibodies, Antinuclear 0
Interferon-alpha 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

21

Subventions

Organisme : CIHR
ID : FRN 159563
Pays : Canada

Informations de copyright

© 2023. The Author(s).

Références

Clin Exp Immunol. 2010 Mar;159(3):281-91
pubmed: 19968664
Rheumatology (Oxford). 2022 Mar 2;61(3):1092-1105
pubmed: 34175923
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Arthritis Res Ther. 2011 Feb 22;13(1):R30
pubmed: 21342502
J Immunol. 2014 Jun 15;192(12):5459-68
pubmed: 24907379
Annu Rev Immunol. 2005;23:307-36
pubmed: 15771573
Ann Rheum Dis. 2011 Nov;70(11):2029-36
pubmed: 21803750
Arthritis Res Ther. 2019 Nov 4;21(1):223
pubmed: 31685018
N Engl J Med. 2003 Oct 16;349(16):1526-33
pubmed: 14561795
Ann Rheum Dis. 2017 Jan;76(1):9-16
pubmed: 27789466
Arthritis Rheumatol. 2014 Jun;66(6):1583-95
pubmed: 24644022
PLoS Biol. 2010 Apr 27;8(4):e1000361
pubmed: 20436908
Biomolecules. 2021 Mar 15;11(3):
pubmed: 33804076
Ann Rheum Dis. 2018 Oct;77(10):1432-1439
pubmed: 29929956
Ann Rheum Dis. 2016 Nov;75(11):2014-2021
pubmed: 27088255
J Leukoc Biol. 2002 Sep;72(3):486-91
pubmed: 12223516
Curr Med Chem. 2010;17(29):3303-8
pubmed: 20712574
Arthritis Res Ther. 2017 Feb 28;19(1):41
pubmed: 28245862
Nature. 1985 Jun 20-26;315(6021):672-6
pubmed: 3925348
Gene. 2016 Jan 15;576(1 Pt 1):14-21
pubmed: 26410416
Arthritis Rheum. 2011 Apr;63(4):1044-53
pubmed: 21162028
J Rheumatol. 2011 Feb;38(2):310-6
pubmed: 21078725
Ann Rheum Dis. 2018 Nov;77(11):1653-1664
pubmed: 30021804
Arthritis Rheum. 2008 Feb;58(2):541-6
pubmed: 18240214
Front Immunol. 2013 Oct 01;4:309
pubmed: 24101921
Scand J Immunol. 2021 Jan;93(1):e12933
pubmed: 32654170
Ann Rheum Dis. 2010 Jul;69(7):1396-402
pubmed: 20472592
Nat Commun. 2020 Dec 1;11(1):6149
pubmed: 33262343
Arthritis Rheum. 1997 Sep;40(9):1725
pubmed: 9324032
Immunity. 2008 Jul 18;29(1):150-64
pubmed: 18631455
Arthritis Rheumatol. 2015 Sep;67(9):2427-36
pubmed: 26109563
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Ann Rheum Dis. 2018 Dec;77(12):1810-1814
pubmed: 30185417
J Immunol. 2002 Apr 1;168(7):3195-204
pubmed: 11907072
Arthritis Rheum. 2001 Mar;44(3):647-52
pubmed: 11263779
J Exp Med. 2003 Mar 17;197(6):711-23
pubmed: 12642603

Auteurs

Sonya T Kim (ST)

Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada.

Carolina Muñoz-Grajales (C)

Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada.
Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Shannon E Dunn (SE)

Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.

Raphael Schneider (R)

Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada.
Division of Neurology, St. Michael's Hospital Unity Health, Toronto, ON, Canada.
Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Sindhu R Johnson (SR)

Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Toronto Scleroderma Program, Division of Rheumatology, Toronto Western and Mount Sinai Hospitals, Toronto, ON, Canada.

Zahi Touma (Z)

Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.

Zareen Ahmad (Z)

Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Toronto Scleroderma Program, Division of Rheumatology, Toronto Western and Mount Sinai Hospitals, Toronto, ON, Canada.

Dennisse Bonilla (D)

Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada.

Eshetu G Atenafu (EG)

Biostatistics Department, Princess Margaret Cancer Center, University Health Network, Toronto, Canada.

Linda T Hiraki (LT)

Division of Rheumatology, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto, Toronto, ON, Canada.

Arthur Bookman (A)

Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Division of Rheumatology, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada.

Joan Wither (J)

Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Canada. joan.wither@uhnresearch.ca.
Department of Immunology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. joan.wither@uhnresearch.ca.
Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. joan.wither@uhnresearch.ca.
Division of Rheumatology, Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada. joan.wither@uhnresearch.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Interferon and interferon-induced cytokines as...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interferon and interferon-induced cytokines as...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Interferon and interferon-induced cytokines as...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Anticorps antinucléaires › Interferon and interferon-induced cytokines as...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies du tissu conjonctif › Rhumatismes › Interferon and interferon-induced cytokines as...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Interférons › Interféron de type I › Interféron alpha › Interferon and interferon-induced cytokines as...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Évolution de la maladie › Interferon and interferon-induced cytokines as...